Scope Fluidics SA
Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. The company offers BacterOMIC, an antibiotic susceptibility testing. Scope Fluidics S.A. was founded in 2010 and is based in Warsaw, Poland.
Scope Fluidics SA (SCP) - Net Assets
Latest net assets as of September 2025: zł115.43 Million PLN
Based on the latest financial reports, Scope Fluidics SA (SCP) has net assets worth zł115.43 Million PLN as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł141.67 Million) and total liabilities (zł26.24 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | zł115.43 Million |
| % of Total Assets | 81.48% |
| Annual Growth Rate | 40.86% |
| 5-Year Change | 342.34% |
| 10-Year Change | N/A |
| Growth Volatility | 681.8 |
Scope Fluidics SA - Net Assets Trend (2015–2024)
This chart illustrates how Scope Fluidics SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Scope Fluidics SA (2015–2024)
The table below shows the annual net assets of Scope Fluidics SA from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | zł146.35 Million | +80.84% |
| 2023-12-31 | zł80.93 Million | -75.69% |
| 2022-12-31 | zł332.97 Million | +2183.45% |
| 2021-12-31 | zł14.58 Million | -55.93% |
| 2020-12-31 | zł33.09 Million | +63.64% |
| 2019-12-31 | zł20.22 Million | +57.89% |
| 2018-12-31 | zł12.81 Million | -24.13% |
| 2017-12-31 | zł16.88 Million | +202.63% |
| 2016-12-31 | zł5.58 Million | -16.76% |
| 2015-12-31 | zł6.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Scope Fluidics SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5225306800.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | zł50.90 Million | 34.78% |
| Common Stock | zł273.00K | 0.19% |
| Other Comprehensive Income | zł23.71 Million | 16.20% |
| Other Components | zł71.47 Million | 48.84% |
| Total Equity | zł146.35 Million | 100.00% |
Scope Fluidics SA Competitors by Market Cap
The table below lists competitors of Scope Fluidics SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NSL Foods Public Company Limited
BK:NSL
|
$52.95 Million |
|
Eagle High Plantations Tbk
JK:BWPT
|
$52.97 Million |
|
Maxi-Cash Financial Services Corporation Ltd
STU:5MX
|
$52.98 Million |
|
INVINITY ENER.SYS EO -01
F:J4Q5
|
$52.99 Million |
|
RCF ACQ.CORP.CL.A -0001
F:GY0
|
$52.91 Million |
|
Famon Awal Bros Sedaya
JK:PRAY
|
$52.90 Million |
|
Hi Sun Technology (China) Limited
PINK:HISNF
|
$52.90 Million |
|
Zomedica Pharmaceuticals Corp
NYSE MKT:ZOM
|
$52.89 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Scope Fluidics SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 80,930,000 to 146,351,000, a change of 65,421,000 (80.8%).
- Net income of 65,421,000 contributed positively to equity growth.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | zł65.42 Million | +44.7% |
| Total Change | zł- | 80.84% |
Book Value vs Market Value Analysis
This analysis compares Scope Fluidics SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.64x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 48.05x to 2.64x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | zł2.95 | zł141.80 | x |
| 2016-12-31 | zł2.46 | zł141.80 | x |
| 2017-12-31 | zł7.33 | zł141.80 | x |
| 2018-12-31 | zł5.53 | zł141.80 | x |
| 2019-12-31 | zł8.73 | zł141.80 | x |
| 2020-12-31 | zł9.11 | zł141.80 | x |
| 2021-12-31 | zł5.43 | zł141.80 | x |
| 2022-12-31 | zł123.38 | zł141.80 | x |
| 2023-12-31 | zł29.69 | zł141.80 | x |
| 2024-12-31 | zł53.69 | zł141.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Scope Fluidics SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 44.70%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 49939.69%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.18x
- Recent ROE (44.70%) is above the historical average (-10.99%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -9.52% | -14.15% | 0.48x | 1.41x | zł-1.31 Million |
| 2016 | -63.11% | -1920.83% | 0.03x | 1.16x | zł-4.08 Million |
| 2017 | -24.72% | -231810.76% | 0.00x | 1.11x | zł-5.86 Million |
| 2018 | -31.81% | 0.00% | 0.00x | 1.09x | zł-5.35 Million |
| 2019 | -31.24% | 0.00% | 0.00x | 1.36x | zł-8.34 Million |
| 2020 | -31.90% | 0.00% | 0.00x | 1.77x | zł-9.79 Million |
| 2021 | -34.73% | 0.00% | 0.00x | 3.62x | zł-6.52 Million |
| 2022 | 95.65% | 78833.91% | 0.00x | 1.04x | zł285.19 Million |
| 2023 | -23.21% | -3640.50% | 0.01x | 1.25x | zł-26.88 Million |
| 2024 | 44.70% | 49939.69% | 0.00x | 1.18x | zł50.79 Million |
Industry Comparison
This section compares Scope Fluidics SA's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $106,348,856
- Average return on equity (ROE) among peers: 23.40%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Scope Fluidics SA (SCP) | zł115.43 Million | -9.52% | 0.23x | $52.93 Million |
| Biomaxima (BMX) | $25.94 Million | 30.64% | 1.06x | $7.70 Million |
| Selvita S.A. (SLV) | $49.19 Million | 21.34% | 0.48x | $129.09 Million |
| Voxel S.A. (VOX) | $243.91 Million | 18.21% | 0.92x | $144.21 Million |